Email updates

Keep up to date with the latest news and content from Diagnostic Pathology and BioMed Central.

Open Access Open Badges Research

Enhancement of recombinant myricetin on the radiosensitivity of lung cancer A549 and H1299 cells

Shijie Zhang1, Lei Wang2, Hongchun Liu1, Guoqiang Zhao3* and Liang Ming1*

Author Affiliations

1 Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, No.1, Jianshe Road, Zhengzhou 450052, PR China

2 Department of Emergency, The First Affiliated Hospital of Zhengzhou University, No.1, Jianshe Road, Zhengzhou 450052, PR China

3 College of Basic Medical Sciences, Zhengzhou University, No.100, Kexue Avenue, Zhengzhou 450001, PR China

For all author emails, please log on.

Diagnostic Pathology 2014, 9:68  doi:10.1186/1746-1596-9-68

Published: 20 March 2014



Myricetin, a common dietary flavonoid is widely distributed in fruits and vegetables, and is used as a health food supplement based on its immune function, anti-oxidation, anti-tumor, and anti-inflammatory properties. The aim of this study was to investigate the effects of myricetin on combination with radiotherapy enhance radiosensitivity of lung cancer A549 and H1299 cells.


A549 cells and H1299 cells were exposed to X-ray with or without myricetin treatment. Colony formation assays, CCK-8 assay, flow cytometry and Caspase-3 level detection were used to evaluate the radiosensitization activity of myricetin on cell proliferation and apoptosis in vitro. Nude mouse tumor xenograft model was built to assessed radiosensitization effect of myricetin in vivo.


Compared with the exposed group without myricetin treatment, the groups treated with myricetin showed significantly suppressed cell surviving fraction and proliferation, increased the cell apoptosis and increased Caspase-3 protein expression after X-ray exposure in vitro. And in vivo assay, growth speed of tumor xenografts was significantly decreased in irradiated mice treated with myricetin.


The study demonstrated both in vitro and in vivo evidence that combination of myricetin with radiotherapy can enhance tumor radiosensitivity of pulmonary carcinoma A549 and H1299 cells, and myricetin could be a potential radiosensitizer for lung cancer therapy.

Virtual slides

The virtual slide(s) for this article can be found here: webcite

Myricetin; Pulmonary carcinoma; Radiosensitizer; Radiotherapy